Psilocybin Microdosing in 2026: Emerging Science, Protocols, and Latin America's Regulatory Boom

As psilocybin microdosing gains attention across Latin America, emerging research from Imperial College and NEJM trials examines therapeutic potential despite inconclusive evidence. The Fadiman Protocol establishes dosing guidelines while Argentina, Mexico, and Brazil develop regulatory frameworks, with the region's first medicinal mushroom law signaling shifting policy landscapes. Scientists emphasize that microdosing research remains preliminary, requiring rigorous clinical validation before widespread medical adoption. Understanding current evidence, dosing ranges, and legal status is essential for healthcare providers and patients in Puerto Rico navigating this evolving therapeutic frontier.